New Developments in Radiotherapy

Guest Editors:

**Prof. Dr. Nicola Curtin**  
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK  
nicola.curtin@newcastle.ac.uk

**Dr. Jason Parsons**  
Department of Molecular and Clinical Cancer Medicine, Cancer Research Centre, University of Liverpool, 200 London Road, Liverpool L3 9TA, UK  
J.Parsons@liverpool.ac.uk

Deadline for manuscript submissions:  
closed (31 October 2018)

Message from the Guest Editors

Dear Colleagues,

More than half of all cancer patients receive radiotherapy as part of their treatment, and 40 % of all patients who are cured of cancer have received radiotherapy. Radiotherapy is also used for palliation and is one of the most cost-effective treatments for cancer. Recent years have seen several major developments in how radiotherapy is given with the use of image-guided high precision external beam radiation such as stereotactic radiotherapy (SBRT and SABR) hypofractionation, proton beam therapy as well as developments in the use of brachytherapy and targeted radionuclides. Moreover several novel combinations beyond the conventional cytotoxic radiosensitisers using molecularly-targeted agents directed at the DNA damage response, hypoxia, metabolism and angiogenesis, as well as immunotherapy agents, are under investigation. These developments have been supported by preclinical investigations that have benefitted from improvements in small animal imaging and irradiation (SARRP). The aim of this Special Issue is to provide an up-to-date overview of these new developments.

Prof. Dr. Nicola Curtin  
Dr. Jason Parsons  
*Guest Editors*
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI